TY - JOUR
T1 - AKI in Hospitalized Patients with and without COVID-19
T2 - A Comparison Study
AU - Neugarten, Joel
AU - Bellin, Eran
AU - Yunes, Milagros
AU - Stahl, Lindsay
AU - Johns, Tanya S.
AU - Abramowitz, Matthew K.
AU - Levy, Rebecca
AU - Kumar, Neelja
AU - Mokrzycki, Michele H.
AU - Coco, Maria
AU - Dominguez, Mary
AU - Prudhvi, Kalyan
AU - Golestaneh, Ladan
AU - Fisher, Molly
N1 - Publisher Copyright:
Copyright © 2020 by the American Society of Nephrology.
PY - 2020/9
Y1 - 2020/9
N2 - Background Reports from centers treating patients with coronavirus disease 2019 (COVID-19) have noted that such patients frequently develop AKI. However, there have been no direct comparisons of AKI in hospitalized patients with and without COVID-19 that would reveal whether there are aspects of AKI risk, course, and outcomes unique to this infection. Methods In a retrospective observational study, we evaluated AKI incidence, risk factors, and outcomes for 3345 adults with COVID-19 and 1265 without COVID-19 who were hospitalized in a large New York City health system and compared them with a historical cohort of 9859 individuals hospitalized a year earlier in the same health system. We also developed a model to identify predictors of stage 2 or 3 AKI in our COVID-19. Results We found higher AKI incidence among patients with COVID-19 compared with the historical cohort (56.9% versus 25.1%, respectively). Patients with AKI and COVID-19 were more likely than those without COVID-19 to require RRT and were less likely to recover kidney function. Development of AKI was significantly associated with male sex, Black race, and older age (.50 years). Male sex and age .50 years associated with the composite outcome of RRT or mortality, regardless of COVID-19 status. Factors that were predictive of stage 2 or 3 AKI included initial respiratory rate, white blood cell count, neutrophil/ lymphocyte ratio, and lactate dehydrogenase level. Conclusions Patients hospitalized with COVID-19 had a higher incidence of severe AKI compared with controls. Vital signs at admission and laboratory data may be useful for risk stratification to predict severe AKI. Although male sex, Black race, and older age associated with development of AKI, these associations were not unique to COVID-19.
AB - Background Reports from centers treating patients with coronavirus disease 2019 (COVID-19) have noted that such patients frequently develop AKI. However, there have been no direct comparisons of AKI in hospitalized patients with and without COVID-19 that would reveal whether there are aspects of AKI risk, course, and outcomes unique to this infection. Methods In a retrospective observational study, we evaluated AKI incidence, risk factors, and outcomes for 3345 adults with COVID-19 and 1265 without COVID-19 who were hospitalized in a large New York City health system and compared them with a historical cohort of 9859 individuals hospitalized a year earlier in the same health system. We also developed a model to identify predictors of stage 2 or 3 AKI in our COVID-19. Results We found higher AKI incidence among patients with COVID-19 compared with the historical cohort (56.9% versus 25.1%, respectively). Patients with AKI and COVID-19 were more likely than those without COVID-19 to require RRT and were less likely to recover kidney function. Development of AKI was significantly associated with male sex, Black race, and older age (.50 years). Male sex and age .50 years associated with the composite outcome of RRT or mortality, regardless of COVID-19 status. Factors that were predictive of stage 2 or 3 AKI included initial respiratory rate, white blood cell count, neutrophil/ lymphocyte ratio, and lactate dehydrogenase level. Conclusions Patients hospitalized with COVID-19 had a higher incidence of severe AKI compared with controls. Vital signs at admission and laboratory data may be useful for risk stratification to predict severe AKI. Although male sex, Black race, and older age associated with development of AKI, these associations were not unique to COVID-19.
UR - http://www.scopus.com/inward/record.url?scp=85090170630&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090170630&partnerID=8YFLogxK
U2 - 10.1681/ASN.2020040509
DO - 10.1681/ASN.2020040509
M3 - Article
C2 - 32669322
AN - SCOPUS:85090170630
SN - 1046-6673
VL - 31
SP - 2145
EP - 2157
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 9
ER -